Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision: 63 days

Cancer Drug Resistance

Articles

Most Recent | Most Viewed | Most Downloaded

Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma

Open Access Review DOI: 10.20517/cdr.2024.54 30 Oct 2024
Views: Downloads:
Download PDF

NFE2L2 and ferroptosis resistance in cancer therapy

Open Access Review DOI: 10.20517/cdr.2024.123 24 Oct 2024
Views: Downloads:
Download PDF

The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models

Open Access Original Article DOI: 10.20517/cdr.2024.53 17 Oct 2024
Views: Downloads:
Download PDF

Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies

Open Access Review DOI: 10.20517/cdr.2024.67 14 Oct 2024
Views: Downloads:
Download PDF

Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers

Open Access Review DOI: 10.20517/cdr.2024.81 26 Sep 2024
Views: Downloads:
Download PDF

Venetoclax resistance: mechanistic insights and future strategies

Open Access Review DOI: 10.20517/cdr.2021.125 5 May 2022
Views: Downloads:
Download PDF

Improving HER2 testing reproducibility in HER2-low breast cancer

Open Access Opinion DOI: 10.20517/cdr.2022.29 31 Aug 2022
Views: Downloads:
Download PDF

Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces

Open Access Review DOI: 10.20517/cdr.2022.20 1 Aug 2022
Views: Downloads:
Download PDF

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
27 Editorial Board members were featured on both the “Career-long Impact” and "Single-year Impact" lists, 4 Editorial Board members were included in the “Career-long Impact” ranking, 17 Editorial Board members were featured in the “Single-year Impact” ran
The journal Cancer Drug Resistance has established a media partnership with the European Association for Cancer Research (EACR) and Boehringer Ingelheim for the upcoming EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway.
We are pleased to announce that our journal, Cancer Drug Resistance (CDR), has obtained a new Impact Factor 2023 of 4.6, as reported by the Journal Citation Reports (JCR) released by Clarivate Analytics on June 20, 2024.
placing the journal in Q1 in the Pharmacology (medical) discipline
Their promotion recognizes their exceptional contributions to the journal and their steadfast dedication to advancing research in the field of cancer drug resistance.

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/